ZymeTx, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials evaluating chemiluminescence film-detection, infectious disease platform for influenza testing will enroll 350 patients at three U.S. sites, the firm reports Feb. 13. Point-of-care testing platform developed with strategic partner Polaroid incorporates high-speed film to chemically capture light emissions produced by proprietary molecules and compounds, which release light in the presence of infectious organisms when activated and produced with Polaroid technology. Slated to conclude this spring, trials will be followed by pivotal studies to support FDA clearance